We have witnessed a number of weak results, attempts for "positive" data misinterpretations and manipulations with TAM in this area which generally make it quite hard to determine real clinical benefit and take time to predict commercial success for the companies involved in the development of new treatment methods for rare autoimmune disorders.
Therefore, I was looking for a company that can change the current conditions and offer a product with transparent data, better efficiency and safety. Especially efficacy and safety together are quite difficult when one has to deal with the complement system.
Apellis